India, March 11 -- Cell therapy company Legend Biotech Corp. (LEGN) on Tuesday reported a profit in its fourth quarter, compared to prior year's loss, with significantly higher revenues.
In pre-market activity on the Nasdaq, Legend Biotech shares were gaining around 1.4 percent to trade at $34.51.
Net income attributable to ordinary equity holders of the parent was $26.28 million or $0.07 per share, compared to prior year's loss of $144.82 million or $0.40 per share.
The increase of $171.1 million was primarily attributable to unrealized foreign currency exchange gains due to changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and Euro.
Adjusted net loss for the period was $59.08 ...